PMID- 25643432
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20191113
IS  - 0001-5385 (Print)
IS  - 0001-5385 (Linking)
VI  - 69
IP  - 6
DP  - 2014 Dec
TI  - The REDUCED (a RandomisED stUdy Comparing standard systemic anticoagulation 
      thErapy to low Dose intracoronary anticoagulation therapy for elective 
      percutaneous coronary intervention) trial. A novel pharmacologic regime for 
      elective percutaneous coronary intervention.
PG  - 619-27
AB  - AIM: This study tried to determine the efficacy and safety of low-dose 
      intracoronary unfractionated heparin (UFH) in elective percutaneous coronary 
      intervention (PCI). METHODS: Two-hundred patients who underwent elective PCI of 
      an uncomplicated lesion were included into the study. The patients were assigned 
      to either a control group (70-100 IU/kg intravenous UFH) or a low-dose 
      intracoronary UFH (1,000 IU intracoronary UFH) group. RESULTS: At 30 days, the 
      primary end point (composite of death, myocardial infarction, or urgent target 
      vessel revascularization) was similar in both groups [intracoronary UFH group, 
      1.0%; control group, 2.0%; odds ratio; 0.49 (95% CI: 0.04 - 5.54), P = 0.56]. 
      Post-procedural myocardial injury (according to CK-MB, P = 0.91; according to Tn 
      I, P = 0.81) and bleeding events (based on TIMI criteria, P = 0.33; based on 
      STEEPLE criteria, P = 0.20) were similar in the control and intracoronary groups. 
      The primary end point at 6 months was also similar between the two groups (P = 
      0.33). Moreover, the health care cost at 30 days of follow-up was lower in the 
      intracoronary group than in the control group (1,016 +/- 54 $/patient vs 1,110 +/- 
      102 $/patient, P < 0.001). CONCLUSION: This pilot study suggests that elective 
      PCI could be safely performed with low-dose intracoronary UFH in the treatment of 
      uncomplicated lesions and at a lower cost as compared to standard systemic 
      anticoagulation.These results should be confirmed by further studies.
FAU - Ari, Hasan
AU  - Ari H
FAU - Kivac, Eylem
AU  - Kivac E
FAU - Ari, Selma
AU  - Ari S
FAU - Emlek, Nadir
AU  - Emlek N
FAU - Cetinkaya, Seckin
AU  - Cetinkaya S
FAU - Celiloglu, Nuran
AU  - Celiloglu N
FAU - Sarigul, O Yasar
AU  - Sarigul OY
FAU - Aydin, Cihan
AU  - Aydin C
FAU - Akkaya, Mehmet
AU  - Akkaya M
FAU - Koca, Vedat
AU  - Koca V
FAU - Bozat, Tahsin
AU  - Bozat T
FAU - Gurdogan, Muhammet
AU  - Gurdogan M
LA  - eng
SI  - ClinicalTrials.gov/NCT01031095
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Coronary Angiography
MH  - Double-Blind Method
MH  - Endpoint Determination
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 2015/02/04 06:00
MHDA- 2015/02/20 06:00
CRDT- 2015/02/04 06:00
PHST- 2015/02/04 06:00 [entrez]
PHST- 2015/02/04 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - 10.1080/ac.69.6.1000004 [doi]
PST - ppublish
SO  - Acta Cardiol. 2014 Dec;69(6):619-27. doi: 10.1080/ac.69.6.1000004.